Clinical trials: Insufficient Response to Methotrexate or Leflunomide
Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide
Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide
Approximately, 40 to 50% of patients with rheumatoid arthritis (RA), the most frequent inflammatory arthritide, are non responders to the consensual 1st line of treatment : methotrexate.
- Trial name
- BIO3 (NCT02714634)
- Testing
- Methotrexate + targeted therapy administration, methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
- Where
- France
- Volunteers
- 286 people
- Sponsor
- University Hospital, Strasbourg, France